Top advisers to Robert F. Kennedy Jr. are battling over how aggressively to target vaccines during his first days as the ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...

The Trump administration has withdrawn a plan to ban menthol cigarettes in the U.S., in a setback to health regulators and ...

A debate over the program for skilled foreign workers has pitted immigration hard-liners against some of President Trump’s ...

Big business has an inside track in the second Trump presidency, and people with a stake in those businesses have reason to ...

The Host Julie Rovner KFF Health News @jrovner Read Julie's stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A ...

Trump then went on to criticize the nation’s electric grid, calling it old while noting that he would allow the tech companies to rely on any fuel that they want to run the plants. And if the energy ...

Diversity, equity and inclusion programs have come under attack in American boardrooms, state legislatures and college ...

An email obtained by NPR says NIH employees are subject to a travel freeze and offers of employment are being rescinded. Scientists worry about disruptions to critical research.

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Novo Nordisk (NVO) has reportedly been criticized by a U.K. pharma industry group for mischaracterizing certain payments to ...